(Q35779054)

10 August 2017

1 reference

title

Schizophrenia, the metabolic syndrome and diabetes (English)

1 reference

10 August 2017

0 references

1 reference

Holt RI

1

1 reference

PubMed ID

15154933

10 August 2017

Peveler RC

series ordinal

2

1 reference

PubMed ID

15154933

10 August 2017

Byrne CD

series ordinal

3

1 reference

10 August 2017

1 June 2004

1 reference

10 August 2017

1 reference

10 August 2017

21

1 reference

10 August 2017

6

1 reference

10 August 2017

515-523

1 reference

Epidemiology of schizophrenia: the global burden of disease and disability

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Effects of Nefazodone on Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Euglycemic clamp study in clozapine-induced diabetic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Prostaglandin E1 suppression of platelet aggregation response in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-naïve, first-episode schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Schizophrenia in the National Academy of Sciences-National Research Council Twin Registry: a 16-year update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Molecular genetics of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Defining the genetic contribution of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

The early origins of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Low birthweight in schizophrenia: prematurity or poor fetal growth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Child development risk factors for adult schizophrenia in the British 1946 birth cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Phenothiazines and Diabetes in Hospitalized Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Clozapine use and risk of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Efficacy should drive atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Dopamine in the lateral hypothalamus may be involved in the inhibition of locomotion related to food and water seeking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Serum leptin levels increase rapidly after initiation of clozapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

Incident Diabetes Associated With Antipsychotic Use in the United Kingdom General Practice Research Debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01199.X

10.1111/J.1464-5491.2004.01199.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15154933